KdT Ventures
VC Fund
Austin, United States
KdT Ventures is an early-stage venture capital firm that invests in startups in the data, engineering, and biology sector, as well as healthcare technology systems, pharmaceuticals, biotechnology, agriculture, chemicals, gases, and life sciences. The firm was founded in 2017 in Austin, Texas by Cain McClary.
- Total investments:
- 94
- Last investment:
- Lead investor:
- 9%
- Fund size:
- $80M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries KdT Ventures invests in
Stages KdT Ventures invests in
Countries KdT Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2.6M–$13M
- Series A
- $9M–$70M
- Series B
- $25M–$175M
Investment Focus
Industry
- Biotechnology 33 (35%)
- Health Care 29 (31%)
- Medical 20 (21%)
- Artificial Intelligence 12 (13%)
- Life Science 9 (10%)
Stage
- Seed 40 (43%)
- Series A 27 (29%)
- Series B 6 (6%)
- Convertible Note 2 (2%)
- Venture - Series Unknown 2 (2%)
Country
- United States 52 (55%)
- India 1 (1%)
- Canada 1 (1%)
- Israel 1 (1%)
- Germany 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrew McClary
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 7 | Find email | |
Phil Grayeski
Principal
|
Principal | Total investments: 0 | Find email | |
|
Ally Gudeman
Head of Operations
|
Head of Operations | Total investments: 0 | Find email | |
Isaac Stoner
Advisor & LP
|
Advisor & LP | Total investments: 0 | Find email | |
Mack Healy
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tacit Therapeutics
|
Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California. | $19M / Series A / Mar 09, 2026 | |
Skeletalis
|
Skeletalis is a biotechnology startup focused on developing next-generation precision medicines for musculoskeletal diseases, primarily osteoporosis. | $8M / Seed / Nov 17, 2025 | |
Zag Bio
|
Zag Bio™ has discovered a novel approach to create thymus-targeted medicines to treat and prevent autoimmune diseases by restoring central immune tolerance. Zag Bio designs bifunctional antibodies that deliver self-antigens to antigen-presenting cells in the thymus to harness the body’s natural process for training immune cells to recognize andtolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes ZAG-101, its lead program for Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases and help patients and their caregivers. Located in Cambridge, Massachusetts, Zag Bio’s team includes experienced experts in thymus biology, autoimmune diseases and innovative drug development.Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases. | $80M / Series A / Oct 28, 2025 | |
Faeth Therapeutics
|
Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy.The company was founded totranslate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians. | $25M / Series A / Oct 20, 2025 | |
PHNX Materials
|
PHNX Materials is a manufacturing company that specializes in turning waste into essential materials and reduce carbon emissions. | $2.5M / Seed / Apr 21, 2025 | |
Character Biosciences
|
Biopharmaceutical research and development company that's an affiliate of Clover Health | $93M / Series B / Mar 25, 2025 | |
Montara Therapeutics
|
Montara Therapeutics is a biotechnology company. | $20M / Seed / Mar 13, 2025 | |
Reverb Therapeutics
|
Reverb Therapeutics engages in the development of treatments for cancer and other diseases. | $12M / Seed / Feb 19, 2025 | |
MacroCycle Technologies
|
MacroCycle is developing a technology to curb the usage of fossil fuel derived plastic through a circular, sustainable and zero-carbon plastic upcycling process. The company's proprietary process based on the synthesis of cyclic macromolecules enables us to produce virgin-grade recycled PET from plastic waste at lower energy use thantraditional processes. | $6.5M / Seed / Feb 06, 2025 | |
Shiprocket
|
Shiprocket is an eCommerce shipping platform that enables cost-effective shipping for direct-to-consumer retailers. Its platform employs a machine-learning-based data engine that recommends proper courier service for a business and chooses a courier company, prints shipping labels, and tracks orders from a single panel that enables businesses tomanage their shipping and returns simply and effectively.The company was founded in 2017 and is headquartered in New Delhi, India. | $25.6M / Series E / Dec 26, 2024 | |
| See all 94 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does KdT Ventures invest in?
KdT Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 94 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is KdT Ventures's check size?
KdT Ventures typically joins rounds of $2.6M–$13M at Seed, $9M–$70M at Series A and $25M–$175M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds KdT Ventures participates in.
How do I contact KdT Ventures?
Public channels for KdT Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at KdT Ventures?
The team at KdT Ventures includes Andrew McClary (Founder and Managing Partner), Phil Grayeski (Principal) and Ally Gudeman (Head of Operations), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
